Axial spondyloarthritis+4
RecruitingStudy on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis
Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis
- Disease:Axial spondyloarthritisJuvenile idiopathic arthritis+3
- Substances:Secukinumab
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Secukinumab
- Sponsor:Novartis Pharma AG









